LivaNovaLIVN
About: UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.
Employees: 2,900
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
156% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $5.14M
31% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 35
5% more funds holding
Funds holding: 231 [Q2] → 242 (+11) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 90
6.69% less ownership
Funds ownership: 102.71% [Q2] → 96.02% (-6.69%) [Q3]
10% less capital invested
Capital invested by funds: $3.05B [Q2] → $2.73B (-$317M) [Q3]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Needham Mike Matson 50% 1-year accuracy 58 / 117 met price target | 58%upside $75 | Buy Reiterated | 25 Nov 2024 |
Mizuho Anthony Petrone 39% 1-year accuracy 15 / 38 met price target | 47%upside $70 | Outperform Maintained | 31 Oct 2024 |
Baird David Rescott 83% 1-year accuracy 10 / 12 met price target | 51%upside $72 | Outperform Maintained | 31 Oct 2024 |
Goldman Sachs David Roman 54% 1-year accuracy 7 / 13 met price target | 37%upside $65 | Buy Initiated | 4 Oct 2024 |
Financial journalist opinion
Based on 3 articles about LIVN published over the past 30 days
